Literature DB >> 17260967

GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease.

Genta Ito1, Takuro Okai, Go Fujino, Kohsuke Takeda, Hidenori Ichijo, Toshiaki Katada, Takeshi Iwatsubo.   

Abstract

Leucine-rich repeat kinase 2 (LRRK2), a product of a causative gene for the autosomal-dominant form of familial Parkinson's disease (PARK8), harbors a Ras-like small GTP binding protein-like (ROC) domain besides the kinase domain, although the relationship between these two functional domains remains elusive. Here we show by thin-layer chromatographic analysis that LRRK2 stably binds GTP but lacks a GTPase activity in HEK293 and Neuro-2a cells. A ROC domain mutation that converts LRRK2 to a guanine nucleotide-free form (T1348N) abolishes the kinase activity of LRRK2 as well as its phosphate incorporation upon metabolic labeling. The phosphorylation of LRRK2 was inhibited by potential inhibitors for cyclic AMP-dependent protein kinase. These data suggest that binding of GTP to the ROC domain regulates the kinase activity of LRRK2 as well as its phosphorylation by other kinase(s).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17260967     DOI: 10.1021/bi061960m

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  122 in total

Review 1.  Genetic mouse models for understanding LRRK2 biology, pathology and pre-clinical application.

Authors:  Zhenyu Yue
Journal:  Parkinsonism Relat Disord       Date:  2012-01       Impact factor: 4.891

2.  Multiple regulatory mechanisms for the Dictyostelium Roco protein GbpC.

Authors:  Arjan Kortholt; Wouter N van Egmond; Katarzyna Plak; Leonard Bosgraaf; Ineke Keizer-Gunnink; Peter J M van Haastert
Journal:  J Biol Chem       Date:  2011-11-26       Impact factor: 5.157

3.  GTP-binding protein-like domain of AGAP1 is protein binding site that allosterically regulates ArfGAP protein catalytic activity.

Authors:  Ruibai Luo; Itoro O Akpan; Ryo Hayashi; Marek Sramko; Valarie Barr; Yoko Shiba; Paul A Randazzo
Journal:  J Biol Chem       Date:  2012-03-27       Impact factor: 5.157

4.  Kinetic, mechanistic, and structural modeling studies of truncated wild-type leucine-rich repeat kinase 2 and the G2019S mutant.

Authors:  Min Liu; Stephanie Kang; Soumya Ray; Justin Jackson; Alexandra D Zaitsev; Scott A Gerber; Gregory D Cuny; Marcie A Glicksman
Journal:  Biochemistry       Date:  2011-10-07       Impact factor: 3.162

5.  Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant.

Authors:  Veronique Daniëls; Renée Vancraenenbroeck; Bernard M H Law; Elisa Greggio; Evy Lobbestael; Fangye Gao; Marc De Maeyer; Mark R Cookson; Kirsten Harvey; Veerle Baekelandt; Jean-Marc Taymans
Journal:  J Neurochem       Date:  2011-01       Impact factor: 5.372

6.  Wild-type LRRK2 but not its mutant attenuates stress-induced cell death via ERK pathway.

Authors:  Anthony K F Liou; Rehana K Leak; Lihua Li; Michael J Zigmond
Journal:  Neurobiol Dis       Date:  2008-07-08       Impact factor: 5.996

Review 7.  Progress in the pathogenesis and genetics of Parkinson's disease.

Authors:  Yoshikuni Mizuno; Nobutaka Hattori; Shin-Ichiro Kubo; Shigeto Sato; Kenya Nishioka; Taku Hatano; Hiroyuki Tomiyama; Manabu Funayama; Yutaka Machida; Hideki Mochizuki
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2008-06-27       Impact factor: 6.237

Review 8.  Role of LRRK2 kinase dysfunction in Parkinson disease.

Authors:  Azad Kumar; Mark R Cookson
Journal:  Expert Rev Mol Med       Date:  2011-06-13       Impact factor: 5.600

9.  GTPase activity plays a key role in the pathobiology of LRRK2.

Authors:  Yulan Xiong; Candice E Coombes; Austin Kilaru; Xiaojie Li; Aaron D Gitler; William J Bowers; Valina L Dawson; Ted M Dawson; Darren J Moore
Journal:  PLoS Genet       Date:  2010-04-08       Impact factor: 5.917

10.  Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways.

Authors:  Rosa M Sancho; Bernard M H Law; Kirsten Harvey
Journal:  Hum Mol Genet       Date:  2009-07-22       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.